Bibliography
- National Multiple Sclerosis SocietyY. Who gets MS? Available from: http://www.nationalmssociety.org/about-multiple-sclerosis/who-gets-ms/index.aspx. [Accessed 11 May 2009]
- Joy J, Johnston R, editors. Multiple sclerosis: current status and strategies for the future. Washington, DC: National Academy Press 2001
- Andersen O, Lycke J, Tollesson P, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996;47(4):895-900
- Karussis D, Meiner Z, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996;47(2):341-6
- Tan I, Lycklama à Nijeholt G, Polman C, et al. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler 2000;6(2):99-104
- Yang J, Xu L, Xiao B, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004;156(1-2):3-9
- Zou L, Abbas N, Volkmann I, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002;42(5):731-9
- Brunmark C, Runström A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;130(1-2):163-72
- Achiron A. Laquinimod reduces level of Il-7 in cultured splenocytes from treated MOG induced EAE and in cultured PBMCs from health human donors. Annual Meeting of the American Academy of Neurology. Chicago, IL. Neurology 2008:A374
- Tuvesson H, Hallin I, Persson R, et al. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab Dispos 2005;33(6):866-72
- Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64(6):987-91
- Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;371(9630):2085-92
- Comi G. Safety and efficacy of orally administered laquinimod for treatment of relapsing remitting multiple sclerosis (RRMS) (ALLEGRO). 2008 November 1, 2008; Available from: http://www.clinicaltrials.gov/ct2/show/NCT00509145 [Cited 4 April 2009]
- Oral laquinimod for multiple sclerosis granted fast track status by FDA [press release]. Jerusalem, Israel: Reuters 2009
- Vollmer DL, Sorensen PS. BRAVO study: Laquinimod double blind placebo controlled study in RRMS patients with a rater blinded reference arm of interferon B-1a (Avonex). 2009 February 17, 2009; Available from: http://www.clinicaltrials.gov/ct2/show/NCT00605215?term = BRAVO&rank = 3 [Cited 6 April 2009]
- Keegan B, Weinshenker B. Laquinimod, a new oral drug for multiple sclerosis. Lancet 2008;371(9630):2059-60